Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer

High Risk Prostate Cancer Clinical Trial

Official title:
Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer

Status Completed

Clinical Trial Summary

Considering the promising results with hypofractionated in low and intermediate risk prostate cancer, our proposal is to translate this experience to patients with high risk prostate cancer. Patients with high risk disease would receive hypofractionated RT to the prostate and to the external and internal iliac lymph nodes using IMRT plus long-term hormonal therapy. The objective of the study is to show that long term grade>2 late toxicity is acceptable and similar to published data using hypofractionated technique in the prostate only.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02107287
Study type	Interventional
Source	McGill University Health Center
Contact
Status	Completed
Phase	N/A
Start date	August 2011
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04236752` - Stereotactic Pelvic Brachytherapy With HDR Boost for Dose Escalation in High Tier Intermediate and High Risk Prostate ca	N/A
Completed	`NCT02268175` - Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate	Phase 2
Completed	`NCT03537391` - Novel Imaging in Staging of Primary Prostate Cancer	N/A
Active, not recruiting	`NCT03340272` - PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.
Recruiting	`NCT05406999` - Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer	Phase 2
Terminated	`NCT01695473` - Neoadjuvant BKM120 in High-risk Prostate Cancer	Phase 2